<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332824</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-272/CCT-101</org_study_id>
    <secondary_id>JapicCTI-142658</secondary_id>
    <secondary_id>U1111-1161-6858</secondary_id>
    <nct_id>NCT02332824</nct_id>
  </id_info>
  <brief_title>A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria</brief_title>
  <official_title>A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Comparison, Phase 2 Study to Evaluate the Dose-response Relationship of the Efficacy and Safety of Oral Administration of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the efficacy and safety on daily oral doses of TAK-272 5
      mg, 20 mg, 40 mg and 80 mg in patients with type 2 diabetes mellitus and microalbuminuria by
      randomized, double-blind, placebo-controlled, parallel-group comparison in order to determine
      the clinical dose of TAK-272.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-272. This study evaluated the dose-response
      relationship of the efficacy and safety of TAK-272 in participants with type 2 diabetes
      mellitus and microalbuminuria.

      The study enrolled 415 patients. Participants were randomly assigned to one of the 6
      treatment groups:

        -  TAK-272 5 mg

        -  TAK-272 20 mg

        -  TAK-272 40 mg

        -  TAK-272 80 mg

        -  Candesartan cilexetil 8 mg

        -  Placebo (dummy inactive pill) for TAK-272 or Candesartan cilexetil - this was a tablet
           that looks like the study drug but had no active ingredient

      All participants were administered tablets, orally at the same time each day for 12 weeks in
      double-blind manner. Participants were administered TAK-272 placebo 4 tablets and Candesartan
      cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and
      follow-up period (Week 12-14).

      This multi-center trial was conducted in Japan. The overall time to participate in this study
      is 22 weeks including 2 weeks of follow-up assessment period after last dose of study drug.
      Participants made multiple visits to the clinic during these periods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2014</start_date>
  <completion_date type="Actual">August 18, 2016</completion_date>
  <primary_completion_date type="Actual">August 18, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12)</measure>
    <time_frame>Week 0 and Week 12</time_frame>
    <description>The first morning void urine (the first urine immediately after rising prior to activities in standing position in the morning) samples on the day of each visit, and 1 day and 2 days before the day of each visit (3 consecutive days) were collected to calculate UACR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine Albumin/Creatinine Ratio (UACR) at Each Assessment Point</measure>
    <time_frame>Weeks 2, 4, 8, 12, follow-up (Week 14) and End of Treatment</time_frame>
    <description>The first morning void urine (the first urine immediately after rising prior to activities in standing position in the morning) samples on the day of each visit, and 1 day and 2 days before the day of each visit (3 consecutive days) were collected to calculate UACR. Reported data is geometric mean ratio of UACR at each assessment point relative to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission Rate From Early-Stage Nephropathy (Stage 2) to Pre-Nephropathy Stage (Stage 1) at the End of Treatment (Week 12)</measure>
    <time_frame>Week 12</time_frame>
    <description>Remission rate is defined as percentage of participants who have UACR &lt;30 mg/gCr and whose UACR decreased by ≥30% from the value at the end of the pre-treatment period (Week 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Rate From Early-Stage Nephropathy (Stage 2) to Overt Nephropathy (Stage 3) During the Treatment Period (Week 12)</measure>
    <time_frame>Week 12</time_frame>
    <description>Progression rate is defined as percentage of participants who have UACR ≥300 mg/gCr and whose UACR increased by ≥30% from the value at the end of the pre-treatment period [Week 0]. Meanwhile, the definition of transition to overt nephropathy also includes the case that UACR decreased to &lt;300 mg/gCr after the transition to overt nephropathy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">415</enrollment>
  <condition>Type 2 Diabetes Mellitus and Microalbuminuria</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet orally, once daily for up to 12 weeks.
Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-272 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-272 5 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-272 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-272 20 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-272 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-272 20 mg 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-272 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-272 20 mg 4 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan cilexetil 8 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAK-272 placebo 4 tablets and Candesartan cilexetil 8 mg one tablet, orally, once daily for up to 12 weeks.
Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-272</intervention_name>
    <description>TAK-272 tablets</description>
    <arm_group_label>TAK-272 20 mg</arm_group_label>
    <arm_group_label>TAK-272 40 mg</arm_group_label>
    <arm_group_label>TAK-272 5 mg</arm_group_label>
    <arm_group_label>TAK-272 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-272 Placebo</intervention_name>
    <description>TAK-272 placebo-matching tablets</description>
    <arm_group_label>Candesartan cilexetil 8 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TAK-272 20 mg</arm_group_label>
    <arm_group_label>TAK-272 40 mg</arm_group_label>
    <arm_group_label>TAK-272 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan cilexetil</intervention_name>
    <description>Candesartan cilexetil tablets</description>
    <arm_group_label>Candesartan cilexetil 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan cilexetil Placebo</intervention_name>
    <description>Candesartan cilexetil placebo-matching tablets</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TAK-272 20 mg</arm_group_label>
    <arm_group_label>TAK-272 40 mg</arm_group_label>
    <arm_group_label>TAK-272 5 mg</arm_group_label>
    <arm_group_label>TAK-272 80 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In the opinion of the investigator or the sub-investigator, the participant is capable
             of understanding and complying with protocol requirements.

          -  The participant signs and dates a written, informed consent form prior to the
             initiation of any study procedures.

          -  The participant is either male or female and aged 20 to less than 75 years at signing
             of informed consent.

          -  The participant is an early-stage nephropathy (Stage 2) patient with type 2 diabetes
             mellitus.

          -  Inpatient/outpatient: outpatient

          -  The participant is a patient with type 2 diabetes mellitus on a certain diet therapy
             and/or exercise therapy (if any).

          -  The participant has stability controlled blood glucose, blood pressure and lipid, and
             does not need any change in the drug and the dose of any antihypertensive,
             antidiabetic and antidyslipidemia or antihyperlipidemic drugs throughout the study
             period as judged by the investigator or the sub-investigator.

          -  The participant has urine albumin/creatinine ratio (UACR) of the first morning urine
             (the first urine immediately after rising prior to activities in standing position in
             the morning) is ≥30 to &lt;300 mg/gCr on at least two of three measurements at the start
             of the pre-treatment period (Week -8), at Week -4 or Week -2.

          -  The participant has estimated glomerular filtration rate according to creatinine
             (eGFRcreat) ≥45 mL/min/1.73 m^2 at Week -4.

          -  A male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent throughout the study period and for 12 weeks after the completion of the
             study.

          -  A female participant of childbearing potential who is sexually active with a
             nonsterilized male partner who agrees to routinely use adequate contraception from
             signing of informed consent until 1 month after the completion of the study.

        Exclusion Criteria:

        &lt;Exclusion Criteria in whole pre-treatment period&gt;

          -  The participant received TAK-272 in a previous clinical study.

          -  The participant is an immediate family member, study site employee, or is in a
             dependent relationship with a study site employee who is involved in the conduct of
             this study (e.g., spouse, parent, child, sibling) or may consent to participate under
             duress.

          -  The participant has a history of hypersensitivity or allergies to TAK-272, candesartan
             cilexetil and other renin-angiotensin system (RAS) inhibitors (angiotensin converting
             enzyme [ACE] inhibitors, angiotensin II receptor blocker [ARBs] or direct renin
             inhibitor [DRIs]).

          -  The participant needs to take the prohibited medications during the study period.

          -  The participant has hyperkalemia (e.g., serum potassium ≥ 5.0 mEq/L at the start of
             the pretreatment period (Week -8) and Week -4 or requiring regular use of a potassium
             adsorbent) or onset of hyperkalemia within 2 years prior to starting the pre-treatment
             period.

          -  The participant has at least class II hypertension (e.g., sitting systolic blood
             pressure [SBP] ≥160 mmHg or sitting diastolic blood pressure [DBP] ≥100 mmHg in the
             pre-treatment period) or malignant hypertension.

          -  The participant has a renal disease other than type 2 diabetic nephropathy (e.g.,
             patients with renal sclerosis, acute or chronic glomerular nephritis, or polycystic
             kidney).

          -  The participant has bilateral or unilateral renal artery stenosis.

          -  The participant requires regular use of nonsteroidal anti-inflammatory drugs
             (excluding low-dose aspirin and locally-acting agents such as topical drugs) (e.g.,
             rheumatoid arthritis patients, osteoarthritis patients, and low back pain patients).

          -  The participant has a history of any of the cardiovascular diseases listed below
             within 2 years prior to starting the pre-treatment period:

               -  Cardiac diseases: myocardial infarction, coronary arterial revascularization

               -  Cerebrovascular diseases: cerebral infarction (excluding lacunar infarction),
                  cerebral hemorrhage, transient ischemic attack

          -  The participant has any of the cardiovascular diseases listed below:

               -  Cardiac diseases: angina pectoris, arrhythmia, and congested heart failure that
                  requires medication

               -  Vascular diseases: arteriosclerosis obliterans with symptoms (e.g., intermittent
                  claudication)

          -  The participant has a clinically significant hepatic disorder (e.g., either of alanine
             aminotransferase [ALT] or aspartate aminotransferase [AST] is ≥ 2.5 times the upper
             limit of normal at the start of the pre-treatment period (Week -8) or at Week -4).

          -  The participant has a complication of malignant tumor.

          -  If female, the participant is pregnant, lactating, or is intending to become pregnant
             before, during or within 1 month after participating in this study; or intending to
             donate ova during such time period.

          -  If male, the participant intends to donate sperm during the course of this study or
             for 12 weeks thereafter.

          -  The participant is judged by the investigator or the sub-investigator as being
             ineligible for any other reason.

        &lt;Exclusion Criteria at the start of the pre-treatment period (Week -8)&gt;

          -  The participant has participated in another clinical study or post-marketing study
             within 30 days prior to starting the pre-treatment period.

          -  The participant has received the study medication within 12 weeks prior to starting
             the pre-treatment period.

          -  The participant has a history of drug abuse (defined as the use of an illicit drug) or
             history of alcohol abuse within 2 years prior to starting the pre-treatment period.

          -  The participant has changed the renin angiotensin system (RAS) inhibitor
             (angiotensin-converting enzyme [ACE] inhibitor, angiotensin II receptor blocker [ARB]
             or direct renin inhibitors [DRI]) or its dose and regimen within 12 weeks prior to
             starting the pre-treatment period.

          -  The participant is treated with any RAS inhibitor (ACE inhibitor, ARB or DRI) at
             signing of informed consent, and whose UACR is &lt;30 mg/gCr at the start of the
             pre-treatment period (Week -8).

        &lt;Exclusion Criteria at Week -4&gt;

          -  The participant has hemoglobin A1c (HbA1c) (National Glycohemoglobin Standardization
             Program [NGSP]) ≥9.0% at Week -4.

          -  The participant has change in HbA1c (NGSP) from the start of the pre-treatment period
             (Week -8) to Week -4 by ≥10.0%* compared to the higher value of them.

             *Second decimal place to be rounded off &lt;Exclusion Criteria at the end of the
             Pre-treatment period (Week 0)&gt;

          -  The participant's sitting SBP and sitting DBP changed by ≥20 mmHg or ≥10 mmHg,
             respectively, at the end of the pre-treatment period (Week 0) compared to Week -2.

          -  The participant's sitting SBP is &lt;130 mmHg at the end of the pre-treatment period
             (Week 0).

          -  The participant's study drug compliance rate* during the pre-treatment period is
             &lt;80.0%.

               -  Compliance rate (%)=(Prescribed amount−Retrieved amount)/ {(Completion date of
                  study drug for the pre-treatment period−Starting date of study drug for the
                  pre-treatment period+1)×5}×100, second decimal place to be rounded off.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kisarazu-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukutsu-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyuushu-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kouriyama-shi</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anchu-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ota-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ishikari-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obihiro-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moriya-shi</city>
        <state>Ibaragi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naka-shi</city>
        <state>Ibaragi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koga</city>
        <state>Ibarakgi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koga-shi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mito-shi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takamatsu-shi</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ebina-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiratsuka-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miura-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shounann-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kochi-shi</city>
        <state>Kochi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yatsushiro-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uji-shi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyazaki-shi</city>
        <state>Miyazaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Azumino-shi</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsumoto-shi</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakano-shi</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sasebo-shi</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasaoka-shi</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naha-shi</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimajiri-gun</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomigusuku-shi</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashiwara-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsubara-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neyagawa-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tondabayashi-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawagoe-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyuki-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka-shi</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koyama-shi</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimono-shi</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hino-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nerima-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjyuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube-shi</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>September 26, 2014</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <results_first_submitted>July 3, 2017</results_first_submitted>
  <results_first_submitted_qc>November 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2018</results_first_posted>
  <last_update_submitted>November 24, 2017</last_update_submitted>
  <last_update_submitted_qc>November 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacological therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Imarikiren hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 81 investigative sites in Japan from 16 Oct 2014 to 18 Aug 2016.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of type 2 diabetes mellitus and microalbuminuria (early-stage nephropathy [Stage 2] patients with type 2 diabetes mellitus) were randomized in 1:1:1:1:1:1 to either of TAK-272 5 mg, 20 mg, 40 mg, 80 mg, candesartan cilexetil 8 mg or Placebo and administered tablets orally once daily for 12 weeks in double-blind manner.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>TAK-272 placebo, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="P2">
          <title>TAK-272 5 mg</title>
          <description>TAK-272 5 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="P3">
          <title>TAK-272 20 mg</title>
          <description>TAK-272 20 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="P4">
          <title>TAK-272 40 mg</title>
          <description>TAK-272 20 mg, 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="P5">
          <title>TAK-272 80 mg</title>
          <description>TAK-272 20 mg, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="P6">
          <title>Candesartan Cilexetil 8 mg</title>
          <description>Candesartan cilexetil 8 mg, one tablet, and TAK-272 placebo 4 tablets, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="69"/>
                <participants group_id="P6" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="66"/>
                <participants group_id="P5" count="65"/>
                <participants group_id="P6" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pretreatment Event/Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inconvenient schedule</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transfer</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized set included all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>TAK-272 placebo, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="B2">
          <title>TAK-272 5 mg</title>
          <description>TAK-272 5 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="B3">
          <title>TAK-272 20 mg</title>
          <description>TAK-272 20 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="B4">
          <title>TAK-272 40 mg</title>
          <description>TAK-272 20 mg, 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="B5">
          <title>TAK-272 80 mg</title>
          <description>TAK-272 20 mg, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="B6">
          <title>Candesartan Cilexetil 8 mg</title>
          <description>Candesartan cilexetil 8 mg, one tablet, and TAK-272 placebo 4 tablets, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="68"/>
            <count group_id="B5" value="69"/>
            <count group_id="B6" value="70"/>
            <count group_id="B7" value="415"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="8.38"/>
                    <measurement group_id="B2" value="61.8" spread="8.90"/>
                    <measurement group_id="B3" value="60.9" spread="9.57"/>
                    <measurement group_id="B4" value="59.6" spread="10.22"/>
                    <measurement group_id="B5" value="61.2" spread="9.95"/>
                    <measurement group_id="B6" value="62.4" spread="9.29"/>
                    <measurement group_id="B7" value="61.3" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="56"/>
                    <measurement group_id="B7" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All participants were enrolled in Japan.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="69"/>
                    <measurement group_id="B6" value="70"/>
                    <measurement group_id="B7" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body Mass Index = weight (kg)/[height (m)^2].</description>
          <population>The analyzed numbers for each arm were participants who were evaluable for this baseline characteristic.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.93" spread="4.024"/>
                    <measurement group_id="B2" value="26.41" spread="4.208"/>
                    <measurement group_id="B3" value="26.91" spread="5.035"/>
                    <measurement group_id="B4" value="26.39" spread="4.580"/>
                    <measurement group_id="B5" value="26.41" spread="3.543"/>
                    <measurement group_id="B6" value="26.60" spread="5.483"/>
                    <measurement group_id="B7" value="26.45" spread="4.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Type 2 Diabetes Mellitus</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.24" spread="8.164"/>
                    <measurement group_id="B2" value="11.48" spread="7.355"/>
                    <measurement group_id="B3" value="11.06" spread="7.708"/>
                    <measurement group_id="B4" value="11.19" spread="7.151"/>
                    <measurement group_id="B5" value="10.88" spread="7.363"/>
                    <measurement group_id="B6" value="10.38" spread="7.046"/>
                    <measurement group_id="B7" value="11.19" spread="7.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concurrent Medical Condition</title>
          <description>Participants may also be counted in more than 1 category.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hypertension - Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension - No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyslipidemia - Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="56"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyslipidemia - No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Medication</title>
          <description>Participants may also be counted in more than 1 category.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Renin-angiotensin system (RAS) Inhibitor - Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAS Inhibitor - No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Glucose Co-transporter (SGLT2)Inhibitor-Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SGLT2 Inhibitor - No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="67"/>
                    <measurement group_id="B6" value="70"/>
                    <measurement group_id="B7" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium-Sparing Diuretic - Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium-Sparing Diuretic - No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="69"/>
                    <measurement group_id="B6" value="69"/>
                    <measurement group_id="B7" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Restricted Medication</title>
          <description>HMG-COA = 3-hydroxy-3-methylglutaryl Coenzyme A. Participants may also be counted in more than 1 category.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Anti-Hypertension Drug - Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hypertension Drug - No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diabetic Drug - Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="65"/>
                    <measurement group_id="B6" value="66"/>
                    <measurement group_id="B7" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diabetic Drug - No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HMG-CoA Reductase Inhibitor - Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HMG-CoA Reductase Inhibitor - No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="74"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine albumin/Creatinine ratio</title>
          <population>The analyzed numbers for each arm were participants who were evaluable for this baseline characteristic.</population>
          <units>mg/gCR</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119.95" lower_limit="65.61" upper_limit="214.88"/>
                    <measurement group_id="B2" value="93.45" lower_limit="53.92" upper_limit="139.41"/>
                    <measurement group_id="B3" value="96.03" lower_limit="58.59" upper_limit="174.45"/>
                    <measurement group_id="B4" value="116.43" lower_limit="49.92" upper_limit="201.16"/>
                    <measurement group_id="B5" value="86.87" lower_limit="53.53" upper_limit="153.05"/>
                    <measurement group_id="B6" value="96.33" lower_limit="57.48" upper_limit="179.26"/>
                    <measurement group_id="B7" value="100.26" lower_limit="55.90" upper_limit="179.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFRcreat</title>
          <description>Male: eGFRcreat (mL/min/1.73 m^2)=194×Cr (mg/dL)^(-1.094)×age (years)^(-0.287) Female: eGFRcreat (mL/min/1.73 m^2)=194×Cr (mg/dL)^(-1.094)×age (years)^(-0.287)×0.739 Cr: serum creatinine</description>
          <population>The analyzed numbers for each arm were participants who were evaluable for this baseline characteristic.</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="72"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="413"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.17" spread="18.828"/>
                    <measurement group_id="B2" value="81.81" spread="19.788"/>
                    <measurement group_id="B3" value="79.19" spread="19.449"/>
                    <measurement group_id="B4" value="80.51" spread="20.292"/>
                    <measurement group_id="B5" value="77.81" spread="18.425"/>
                    <measurement group_id="B6" value="83.27" spread="22.777"/>
                    <measurement group_id="B7" value="79.97" spread="19.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Haemoglobin A1c (HbA1c)</title>
          <population>The analyzed numbers for each arm were participants who were evaluable for this baseline characteristic.</population>
          <units>percentage of glycated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.02" spread="0.789"/>
                    <measurement group_id="B2" value="7.03" spread="0.772"/>
                    <measurement group_id="B3" value="7.06" spread="0.770"/>
                    <measurement group_id="B4" value="7.03" spread="0.789"/>
                    <measurement group_id="B5" value="6.90" spread="0.834"/>
                    <measurement group_id="B6" value="7.02" spread="0.731"/>
                    <measurement group_id="B7" value="7.01" spread="0.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trough Sitting Diastolic Blood Pressure</title>
          <population>The analyzed numbers for each arm were participants who were evaluable for this baseline characteristic.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.6" spread="9.29"/>
                    <measurement group_id="B2" value="80.6" spread="8.80"/>
                    <measurement group_id="B3" value="80.6" spread="8.99"/>
                    <measurement group_id="B4" value="79.3" spread="9.26"/>
                    <measurement group_id="B5" value="81.9" spread="8.90"/>
                    <measurement group_id="B6" value="80.5" spread="8.89"/>
                    <measurement group_id="B7" value="80.6" spread="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trough Sitting Systolic Blood Pressure</title>
          <population>The analyzed numbers for each arm were participants who were evaluable for this baseline characteristic.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="70"/>
                    <count group_id="B7" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141.1" spread="7.01"/>
                    <measurement group_id="B2" value="139.0" spread="8.41"/>
                    <measurement group_id="B3" value="138.2" spread="7.09"/>
                    <measurement group_id="B4" value="139.0" spread="7.64"/>
                    <measurement group_id="B5" value="140.3" spread="7.77"/>
                    <measurement group_id="B6" value="140.6" spread="7.65"/>
                    <measurement group_id="B7" value="139.7" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12)</title>
        <description>The first morning void urine (the first urine immediately after rising prior to activities in standing position in the morning) samples on the day of each visit, and 1 day and 2 days before the day of each visit (3 consecutive days) were collected to calculate UACR.</description>
        <time_frame>Week 0 and Week 12</time_frame>
        <population>Full analysis set (FAS) included all participants who were randomized and received at least one dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>TAK-272 placebo, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O2">
            <title>TAK-272 5 mg</title>
            <description>TAK-272 5 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O3">
            <title>TAK-272 20 mg</title>
            <description>TAK-272 20 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O4">
            <title>TAK-272 40 mg</title>
            <description>TAK-272 20 mg, 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O5">
            <title>TAK-272 80 mg</title>
            <description>TAK-272 20 mg, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O6">
            <title>Candesartan Cilexetil 8 mg</title>
            <description>Candesartan cilexetil 8 mg, one tablet, and TAK-272 placebo 4 tablets, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12)</title>
          <description>The first morning void urine (the first urine immediately after rising prior to activities in standing position in the morning) samples on the day of each visit, and 1 day and 2 days before the day of each visit (3 consecutive days) were collected to calculate UACR.</description>
          <population>Full analysis set (FAS) included all participants who were randomized and received at least one dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>log (mg/gCr)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.152" lower_limit="0.0389" upper_limit="0.2655"/>
                    <measurement group_id="O2" value="-0.173" lower_limit="-0.2848" upper_limit="-0.0602"/>
                    <measurement group_id="O3" value="-0.317" lower_limit="-0.4245" upper_limit="-0.2095"/>
                    <measurement group_id="O4" value="-0.478" lower_limit="-0.5904" upper_limit="-0.3661"/>
                    <measurement group_id="O5" value="-0.497" lower_limit="-0.6081" upper_limit="-0.3867"/>
                    <measurement group_id="O6" value="-0.377" lower_limit="-0.4872" upper_limit="-0.2678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>In the primary analysis, each TAK-272 group will be compared with placebo group based on a step-down testing procedure, which will be employed for multiple comparison adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.325</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4845</ci_lower_limit>
            <ci_upper_limit>-0.1649</ci_upper_limit>
            <estimate_desc>Estimated Value was for LS mean differences (TAK-272 5 mg−placebo) in log-transformed UACR changes from baseline to the end of treatment period.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>In the primary analysis, each TAK-272 group will be compared with placebo group based on a step-down testing procedure, which will be employed for multiple comparison adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.469</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6251</ci_lower_limit>
            <ci_upper_limit>-0.3132</ci_upper_limit>
            <estimate_desc>Estimated Value was for LS mean differences (TAK-272 20 mg−placebo) in log-transformed UACR changes from baseline to the end of treatment period.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>In the primary analysis, each TAK-272 group will be compared with placebo group based on a step-down testing procedure, which will be employed for multiple comparison adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.630</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7897</ci_lower_limit>
            <ci_upper_limit>-0.4711</ci_upper_limit>
            <estimate_desc>Estimated Value was for LS mean differences (TAK-272 40 mg −placebo) in log-transformed UACR changes from baseline to the end of treatment period.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>In the primary analysis, each TAK-272 group will be compared with placebo group based on a step-down testing procedure, which will be employed for multiple comparison adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.650</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8083</ci_lower_limit>
            <ci_upper_limit>-0.4908</ci_upper_limit>
            <estimate_desc>Estimated Value was for LS mean differences (TAK-272 80 mg −placebo) in log-transformed UACR changes from baseline to the end of treatment period.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>In the primary analysis, each TAK-272 group will be compared with placebo group based on a step-down testing procedure, which will be employed for multiple comparison adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.530</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6874</ci_lower_limit>
            <ci_upper_limit>-0.3719</ci_upper_limit>
            <estimate_desc>Estimated Value was for LS mean differences (Candesartan cilexetil 8 mg −placebo group) in log-transformed UACR changes from baseline to the end of treatment period.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Albumin/Creatinine Ratio (UACR) at Each Assessment Point</title>
        <description>The first morning void urine (the first urine immediately after rising prior to activities in standing position in the morning) samples on the day of each visit, and 1 day and 2 days before the day of each visit (3 consecutive days) were collected to calculate UACR. Reported data is geometric mean ratio of UACR at each assessment point relative to Baseline.</description>
        <time_frame>Weeks 2, 4, 8, 12, follow-up (Week 14) and End of Treatment</time_frame>
        <population>The FAS included all participants who were randomized and received at least one dose of the study drug for the treatment period. The analyzed numbers for each arm were participants who were evaluable for this outcome measure at particular timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>TAK-272 placebo, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O2">
            <title>TAK-272 5 mg</title>
            <description>TAK-272 5 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O3">
            <title>TAK-272 20 mg</title>
            <description>TAK-272 20 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O4">
            <title>TAK-272 40 mg</title>
            <description>TAK-272 20 mg, 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O5">
            <title>TAK-272 80 mg</title>
            <description>TAK-272 20 mg, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O6">
            <title>Candesartan Cilexetil 8 mg</title>
            <description>Candesartan cilexetil 8 mg, one tablet, and TAK-272 placebo 4 tablets, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Albumin/Creatinine Ratio (UACR) at Each Assessment Point</title>
          <description>The first morning void urine (the first urine immediately after rising prior to activities in standing position in the morning) samples on the day of each visit, and 1 day and 2 days before the day of each visit (3 consecutive days) were collected to calculate UACR. Reported data is geometric mean ratio of UACR at each assessment point relative to Baseline.</description>
          <population>The FAS included all participants who were randomized and received at least one dose of the study drug for the treatment period. The analyzed numbers for each arm were participants who were evaluable for this outcome measure at particular timepoint.</population>
          <units>mg/gCr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="69"/>
                    <count group_id="O6" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.979" upper_limit="1.112"/>
                    <measurement group_id="O2" value="0.84" lower_limit="0.767" upper_limit="0.929"/>
                    <measurement group_id="O3" value="0.80" lower_limit="0.736" upper_limit="0.873"/>
                    <measurement group_id="O4" value="0.73" lower_limit="0.678" upper_limit="0.795"/>
                    <measurement group_id="O5" value="0.72" lower_limit="0.659" upper_limit="0.797"/>
                    <measurement group_id="O6" value="0.76" lower_limit="0.708" upper_limit="0.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="67"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.930" upper_limit="1.132"/>
                    <measurement group_id="O2" value="0.82" lower_limit="0.742" upper_limit="0.901"/>
                    <measurement group_id="O3" value="0.80" lower_limit="0.731" upper_limit="0.881"/>
                    <measurement group_id="O4" value="0.66" lower_limit="0.605" upper_limit="0.722"/>
                    <measurement group_id="O5" value="0.71" lower_limit="0.638" upper_limit="0.781"/>
                    <measurement group_id="O6" value="0.72" lower_limit="0.668" upper_limit="0.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.974" upper_limit="1.182"/>
                    <measurement group_id="O2" value="0.85" lower_limit="0.772" upper_limit="0.942"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.686" upper_limit="0.817"/>
                    <measurement group_id="O4" value="0.63" lower_limit="0.569" upper_limit="0.688"/>
                    <measurement group_id="O5" value="0.62" lower_limit="0.552" upper_limit="0.690"/>
                    <measurement group_id="O6" value="0.71" lower_limit="0.639" upper_limit="0.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="1.025" upper_limit="1.238"/>
                    <measurement group_id="O2" value="0.85" lower_limit="0.760" upper_limit="0.947"/>
                    <measurement group_id="O3" value="0.71" lower_limit="0.631" upper_limit="0.793"/>
                    <measurement group_id="O4" value="0.61" lower_limit="0.546" upper_limit="0.685"/>
                    <measurement group_id="O5" value="0.59" lower_limit="0.519" upper_limit="0.672"/>
                    <measurement group_id="O6" value="0.70" lower_limit="0.630" upper_limit="0.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Week 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="63"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0.985" upper_limit="1.255"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.830" upper_limit="1.031"/>
                    <measurement group_id="O3" value="0.95" lower_limit="0.861" upper_limit="1.055"/>
                    <measurement group_id="O4" value="0.80" lower_limit="0.725" upper_limit="0.872"/>
                    <measurement group_id="O5" value="0.86" lower_limit="0.770" upper_limit="0.966"/>
                    <measurement group_id="O6" value="0.85" lower_limit="0.771" upper_limit="0.936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="67"/>
                    <count group_id="O5" value="69"/>
                    <count group_id="O6" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="1.048" upper_limit="1.267"/>
                    <measurement group_id="O2" value="0.85" lower_limit="0.760" upper_limit="0.947"/>
                    <measurement group_id="O3" value="0.72" lower_limit="0.644" upper_limit="0.815"/>
                    <measurement group_id="O4" value="0.62" lower_limit="0.552" upper_limit="0.693"/>
                    <measurement group_id="O5" value="0.61" lower_limit="0.540" upper_limit="0.698"/>
                    <measurement group_id="O6" value="0.69" lower_limit="0.616" upper_limit="0.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission Rate From Early-Stage Nephropathy (Stage 2) to Pre-Nephropathy Stage (Stage 1) at the End of Treatment (Week 12)</title>
        <description>Remission rate is defined as percentage of participants who have UACR &lt;30 mg/gCr and whose UACR decreased by ≥30% from the value at the end of the pre-treatment period (Week 0).</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who were randomized and received at least one dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>TAK-272 placebo, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O2">
            <title>TAK-272 5 mg</title>
            <description>TAK-272 5 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O3">
            <title>TAK-272 20 mg</title>
            <description>TAK-272 20 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O4">
            <title>TAK-272 40 mg</title>
            <description>TAK-272 20 mg, 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O5">
            <title>TAK-272 80 mg</title>
            <description>TAK-272 20 mg, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O6">
            <title>Candesartan Cilexetil 8 mg</title>
            <description>Candesartan cilexetil 8 mg, one tablet, and TAK-272 placebo 4 tablets, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Rate From Early-Stage Nephropathy (Stage 2) to Pre-Nephropathy Stage (Stage 1) at the End of Treatment (Week 12)</title>
          <description>Remission rate is defined as percentage of participants who have UACR &lt;30 mg/gCr and whose UACR decreased by ≥30% from the value at the end of the pre-treatment period (Week 0).</description>
          <population>The FAS included all participants who were randomized and received at least one dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.000" upper_limit="5.436"/>
                    <measurement group_id="O2" value="9.0" lower_limit="3.358" upper_limit="18.480"/>
                    <measurement group_id="O3" value="9.5" lower_limit="3.888" upper_limit="18.524"/>
                    <measurement group_id="O4" value="17.9" lower_limit="9.612" upper_limit="29.196"/>
                    <measurement group_id="O5" value="24.6" lower_limit="15.055" upper_limit="36.490"/>
                    <measurement group_id="O6" value="14.3" lower_limit="7.069" upper_limit="24.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Rate From Early-Stage Nephropathy (Stage 2) to Overt Nephropathy (Stage 3) During the Treatment Period (Week 12)</title>
        <description>Progression rate is defined as percentage of participants who have UACR ≥300 mg/gCr and whose UACR increased by ≥30% from the value at the end of the pre-treatment period [Week 0]. Meanwhile, the definition of transition to overt nephropathy also includes the case that UACR decreased to &lt;300 mg/gCr after the transition to overt nephropathy.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who were randomized and received at least one dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>TAK-272 placebo, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O2">
            <title>TAK-272 5 mg</title>
            <description>TAK-272 5 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O3">
            <title>TAK-272 20 mg</title>
            <description>TAK-272 20 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O4">
            <title>TAK-272 40 mg</title>
            <description>TAK-272 20 mg, 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O5">
            <title>TAK-272 80 mg</title>
            <description>TAK-272 20 mg, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O6">
            <title>Candesartan Cilexetil 8 mg</title>
            <description>Candesartan cilexetil 8 mg, one tablet, and TAK-272 placebo 4 tablets, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Rate From Early-Stage Nephropathy (Stage 2) to Overt Nephropathy (Stage 3) During the Treatment Period (Week 12)</title>
          <description>Progression rate is defined as percentage of participants who have UACR ≥300 mg/gCr and whose UACR increased by ≥30% from the value at the end of the pre-treatment period [Week 0]. Meanwhile, the definition of transition to overt nephropathy also includes the case that UACR decreased to &lt;300 mg/gCr after the transition to overt nephropathy.</description>
          <population>The FAS included all participants who were randomized and received at least one dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="9.764" upper_limit="29.607"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.364" upper_limit="10.371"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.000" upper_limit="4.863"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.000" upper_limit="5.357"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.000" upper_limit="5.206"/>
                    <measurement group_id="O6" value="1.4" lower_limit="0.036" upper_limit="7.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
        <time_frame>Up to Week 14</time_frame>
        <population>Safety analysis set included all participants who received at least one dose of the study drug for the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>TAK-272 placebo, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O2">
            <title>TAK-272 5 mg</title>
            <description>TAK-272 5 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O3">
            <title>TAK-272 20 mg</title>
            <description>TAK-272 20 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O4">
            <title>TAK-272 40 mg</title>
            <description>TAK-272 20 mg, 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O5">
            <title>TAK-272 80 mg</title>
            <description>TAK-272 20 mg, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
          <group group_id="O6">
            <title>Candesartan Cilexetil 8 mg</title>
            <description>Candesartan cilexetil 8 mg, one tablet, and TAK-272 placebo 4 tablets, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
          <population>Safety analysis set included all participants who received at least one dose of the study drug for the treatment period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 14</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>TAK-272 placebo, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="E2">
          <title>TAK-272 5 mg</title>
          <description>TAK-272 5 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="E3">
          <title>TAK-272 20 mg</title>
          <description>TAK-272 20 mg, one tablet, TAK-272 placebo 3 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="E4">
          <title>TAK-272 40 mg</title>
          <description>TAK-272 20 mg, 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="E5">
          <title>TAK-272 80 mg</title>
          <description>TAK-272 20 mg, 4 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
        <group group_id="E6">
          <title>Candesartan Cilexetil 8 mg</title>
          <description>Candesartan cilexetil 8 mg, one tablet, and TAK-272 placebo 4 tablets, orally, once daily for up to 12 weeks. Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

